FibroGen Inc reports results for the quarter ended September 30 - Earnings Summary

• FibroGen Inc FGEN.OQ reported a quarterly adjusted loss of 17 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -52 cents. The mean expectation of two analysts for the quarter was for a loss of 30 cents per share. Wall Street expected results to range from -38 cents to -23 cents per share.

• Revenue rose 15.4% to $46.33 million from a year ago; analysts expected $34.76 million.

• FibroGen Inc's reported EPS for the quarter was a loss of 17 cents​.

• The company reported a quarterly loss of $17.08 million.

• FibroGen Inc shares had fallen by 15.2% this quarter and lost 61.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is "sell."

Wall Street's median 12-month price target for FibroGen Inc is $0.60

This summary was machine generated from LSEG data November 12 at 11:27 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)